- •The transplant literature has identified an association between sirolimus therapy and wound complications, but similar studies have not been performed in children with vascular anomalies.
- •Sirolimus may not significantly increase perioperative complication rates (including wound complications) in pediatric patients undergoing resection of their vascular anomaly.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
ISSVA Classification of Vascular Anomalies. 2018. (Accessed Feb 16, 2022, at https://www.issva.org/classification.)
- Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.Pediatrics. 2016; 137
- Sirolimus for the treatment of complicated vascular anomalies in children.Pediatr Blood Cancer. 2011; 57: 1018-1024
- Sirolimus for the Treatment of a Massive Capillary-Lymphatico-Venous Malformation: A Case Report.Pediatrics (Evanston). 2015; 136: e513-e516
- Sirolimus for the treatment of children with various complicated vascular anomalies.European journal of pediatrics. 2015; 174: 1579-1584
- Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone: Treatment of VLM with sirolimus and steroid.Dermatologic therapy. 2015; 28: 218-221
- Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.Clinical imaging. 2015; 39: 529-532
- Medical Therapy for Pediatric Vascular Anomalies.Seminars in plastic surgery. 2014; 28: 79-86
- The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.Orphanet journal of rare diseases. 2019; 14: 141
- Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.Transplantation. 2012; 94: 547-561
- Surgical wound-healing complications in heart transplant recipients treated with rapamycin.Wound Repair Regen. 2007; 15: 316-321
- Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study.Transplantation. 2003; 76: 426-429
- Comparison of Sirolimus vs. Mycophenolate Mofetil on Surgical Complications and Wound Healing in Adult Kidney Transplantation.American journal of transplantation. 2003; 3: 1128-1134
- Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus.Transplantation. 2004; 77: 1555
- A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients.Transplantation. 2009; 87: 296-302
- Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures.Pediatr Transplant. 2018; 22
- Early Sirolimus-Based Immunosuppression is Safe for Lung Transplantation Patients: Retrospective, Single Arm, Exploratory Study.Ann Transplant. 2018; 23: 598-607
- The presentation and management of hemangiomas.Plast Reconstr Surg. 2009; 123 (91e): 181e
- Surgical management of vascular anomalies in children at a tertiary care hospital in a resource-limited setting: a Tanzanian experience with 134 patients.BMC Res Notes. 2015; 8: 732
- Congenital vascular lesions: clinical application of a new classification.J Pediatr Surg. 1983; 18: 894-900
- Surgical approach for venous malformation in the head and neck.Arch Craniofac Surg. 2019; 20: 304-309
- 30-Day outcomes analysis of NSQIP-pediatric for surgical management of head and neck lymphatic malformations in children.Int J Pediatr Otorhinolaryngol. 2019; 118: 21-24
- Thirty-day perioperative outcomes in resection of cervical lymphatic malformations.Int J Pediatr Otorhinolaryngol. 2018; 106: 31-34
- Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice.J Immunol. 2008; 181: 3974-3983